Navigation Links
ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
Date:10/28/2009

LEUVEN, Belgium and LUND, Sweden, October 28 /PRNewswire-FirstCall/ --

- Recruitment of 315 Patients Completed Ahead of Schedule - Results Anticipated in the second quarter of 2010

ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce that they have completed recruitment of their Phase II trial of TB-402 ahead of schedule. TB-402 is a novel, long acting anticoagulant that is being developed for the prevention of deep vein thrombosis (DVT) following orthopaedic surgery. The results of this study, which has recruited 315 patients, are anticipated in the second quarter of 2010.

TB-402 has the potential to be a very important new entrant into the anticoagulant market. TB-402 is a recombinant human monoclonal antibody that partially inhibits Factor VIII, a key component of the coagulation cascade. This novel mode of action is expected to reduce the risk of undesirable bleeding events, even at high doses, as well as the need for patient monitoring. These are the two main drawbacks associated with current anticoagulant therapy. In addition, TB-402 is a long-acting agent, which means it could be given as a single dose to prevent the development of DVT in patients undergoing surgery. This would be an attractive option, as all current anticoagulant treatment options require daily treatment for up to several weeks.

The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomised, open label trial evaluating TB-402 for the prophylaxis of DVT after knee surgery. The study is assessing three different doses of TB-402 (0.3, 0.6 and 1.2 mg/kg) each given as a single intravenous bolus injection post knee replacement surgery. The objective of the study is to assess the safety and efficacy of the three escalating doses of TB-402. The study enrolled a total of 315 patients across 30 centers, mainly in Eur
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
2. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
3. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
4. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
5. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
6. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
7. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
8. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
9. Elekta Provides Complete Planning, Treatment and Workflow Solution for Roy and Patricia Disney Family Cancer Center
10. Delcath Systems, Inc. Completes Phase III Study Enrollment
11. Abbott Completes Visiogen Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... DIEGO and CARDIFF-BY-THE-SEA, Calif. ... Inc. (NASDAQ: SRNE ;  Sorrento), an ... associated pain, and Conkwest, Inc., a privately-held immuno-oncology ... Natural Killer (NK) cell-line based therapy, announced today ... agreement to jointly develop next generation CAR-TNK™ (pronounced ...
(Date:12/19/2014)... 18, 2014  Decision Resources Group finds that the ... will increase to a value of over ... by expansion in the large direct energy device market. ... increasingly adopted due to the advantages they offer and ... findings from Decision Resources Group,s coverage of the U.S. ...
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... University Medical Pharmaceuticals, which specializes in developing and distributing ... to the mass market, announced today that it has ... , Mr. Ten brings 28 years of ... luxury and consumer packaged goods industry. At University ...
... Inc., a company leading the scientific research of neurogenesis ... identify novel pathways for the treatment of central nervous ... Scolnick from the Broad Institute of MIT and Harvard ... to its scientific advisory board. The appointees join BrainCells, ...
Cached Medicine Technology:University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales 2University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales 3BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman 2BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman 3
(Date:12/20/2014)... 20, 2014 Angeldress.co.uk, the distinguished wedding ... for worldwide dress fans. The company has recently updated ... information. For the holiday season, Angeldress Blog ... wedding apparel. , Angeldress.co.uk prides itself in offering a ... of service. All the company’s outfits are very carefully ...
(Date:12/20/2014)... York, NY (PRWEB) December 20, 2014 The ... has caused quite a stir, not only in Hollywood, but ... on December 18th , the ripples of that attack are ... executives’ very jobs at risk. But they are not ... correspondences exposed could be in for some embarrassing times ahead, ...
(Date:12/20/2014)... December 20, 2014 Xarelto bleeding ... suffered uncontrollable bleeding and other serious side effects ... District of Louisiana for coordinated pretrial proceedings, Wright & ... Litigation (JPML) issued an order Friday to transfer 21 ... in 22 federal courts to the Louisiana district court ...
(Date:12/20/2014)... Today, Balfleet.com, one of the most outstanding dressmakers in ... on its Mother of the Bride Dresses ... bride dresses from Balfleet.com feature gorgeous looks and delicate ... pride in providing high quality dresses to its clients ... on our mother of the bride dresses, and we ...
(Date:12/19/2014)... 2014 Sweetdressy.com , a leading ... its newest selection of cheap prom dresses for ladies ... in the world and clients can buy these dresses ... prom dresses feature cool cuts and delicate craftsmanship, and ... the middle-end market. Discount shipping costs are available for ...
Breaking Medicine News(10 mins):Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2
... Actress and best-selling author,Jenny McCarthy has established herself ... autism cure and advocate for nutritional regimens to ... Health Trax(TM) (GHT) flagship,specialty probiotic product, ThreeLac(TM), into ... in her book Louder than,Words: A Mother,s Journey ...
... fails to ease symptoms, but old drug offers new hope ... step forward, one step back in the search for treatments ... the July 19 issue of The Lancet , an ... a second report, a once-promising vaccine failed to prevent the ...
... Women Veterans, WASHINGTON, July 18 Dr. Paula ... Traumatic,Stress Disorder (PTSD), received the 3rd annual Ladies Home ... women veterans., "Dr. Schnurr,s contribution to veterans is ... who have borne the battle,",said Secretary of Veterans Affairs ...
... the earliest events occurring immediately upon infection with HIV-I ... the immune system earlier than was previously understood. According ... the window of opportunity for successful intervention may be ... after transmission, as researchers had previously believed. , Appearing ...
... patients develop resistance to chemotherapy drugs, sometimes abruptly, after ... working well to reduce tumors or hold them in ... result when this occurs is all too familiar: patients ... become resistant. , A team of researchers at Cold ...
... Proposed Acquisition to Strengthen Existing Therapeutic Focus Through ... Extending the ... 18 /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: BJGP; "BMP Sunstone"; ... Co., Ltd. ("Sunstone") has signed a non-binding letter of,intent ...
Cached Medicine News:Health News:Global Health Trax Joins Fight Against Autism With Jenny McCarthy and Generation Rescue 2Health News:Alzheimer's Research Brings Progress, Setbacks 2Health News:Alzheimer's Research Brings Progress, Setbacks 3Health News:Alzheimer's Research Brings Progress, Setbacks 4Health News:HIV conquers immune system faster than previously realized 2Health News:HIV conquers immune system faster than previously realized 3Health News:CSHL scientists correlate enzyme expression levels with chemotherapy drug response 2Health News:CSHL scientists correlate enzyme expression levels with chemotherapy drug response 3Health News:CSHL scientists correlate enzyme expression levels with chemotherapy drug response 4Health News:BMP Sunstone Signs Letter of Intent to Acquire Shengda Pharmaceutical Co. 2Health News:BMP Sunstone Signs Letter of Intent to Acquire Shengda Pharmaceutical Co. 3
... Bledsoe Sport & Sport Max patellofemoral knee ... and/or collateral injuries. Patients with minor knee ... can benefit from added support to prevent ... designs to provide the right kind of ...
... Brace gives fracture treatment patients maximum support ... brace features the the Bledsoe Multi-Centric Hinge, ... and positively locks at any angle within ... slots, the Bledsoe Multi-Centric Hinge anatomically tracks ...
... The Bledsoe Revolution ... for speed fitting under ... frees the surgeon or ... time-consuming post-op fitting and ...
The Bledsoe Post-Op Knee Brace is designed to provide maximum protection without sacrificing comfort and quick, easy application....
Medicine Products: